May 30, 2017
Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies […]
May 30, 2017
AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology […]
May 30, 2017
Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic […]
May 30, 2017
AbbVie will present a total of 23 abstracts across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors. Researchers will present efficacy and safety data on depatuxizumab mafodotin, an antibody-drug conjugate (ADC) being studied for the treatment of adults with amplified EGFR newly […]
May 28, 2017
Liquid Biopsy is a term given to a minimally invasive method of analyzing Tumor cell DNA circulating in the blood. This is a useful and very promising approach and opens new vistas compared to the Biochemical Biomarkers and Tissue Biopsies dependent monitoring of cancer. However, it throws its own challenges […]
May 28, 2017
At ASCO 2017, the steadily increasing competitive intensity between Lonsurf (TAS-102, Taiho) and Stivarga (regorafenib, Bayer) will be on display . In addition, the I/O agents are reading out both as monotherapy in specific (dMMR/MSI-H) patient segments, as well as in combinations with other cytotoxic and targeted agents in broader patient […]